Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer

Oncology

Volumn 77, Issue SUPPL. 1, 2010, Pages 23-37

  Arpino, Grazia ^a   De Angelis, Carmine ^a   Giuliano, Mario ^a   Giordano, Antonio ^a   Falato, Claudette ^a   De Laurentiis, Michele ^a   De Placido, Sabino ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Aromatase inhibitors; Breast cancer; Cross talk; Endocrine resistance; Endocrine therapy; Epidermal growth factor receptor; Estrogen receptor; HER2; Hormone therapy; Progesterone receptor; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEFITINIB; GROWTH FACTOR; LAPATINIB; LETROZOLE; PERTUZUMAB; RALOXIFENE; RAPAMYCIN; TAMOXIFEN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; GENOMICS; HORMONAL THERAPY; HUMAN; MOLECULAR INTERACTION; MONOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR GROWTH; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; ENDOCRINE SYSTEM; FEMALE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; ENDOCRINE SYSTEM; FEMALE; HUMANS;

EID: 77949905085     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000258493     Document Type: Review

References (78)

1. Group EBCTC: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
2. Gradishar WJ: Tamoxifen: what next? Oncologist 2004; 9: 378-384.
3. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
4. Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M: Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 2003; 9: 524S-532S.
5. Lonning PE: Aromatase inhibitors in breast cancer. Endocr Relat Cancer 2004; 11: 179-189.
6. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
7. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor- positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262-1271.
8. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
9. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
10. Osborne CK, Schiff R: Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005; 23: 1616-1622.
11. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK: Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004; 10: 331S-336S.
12. Lee AV, Cui X, Oesterreich S: Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 2001; 7: 4429s-4435s; discussion 4411s-4412s.
13. Osborne CK, Schiff R, Fuqua SA, Shou J: Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001; 7: 4338s-4342s; discussion 4411s-4412s.
14. Speirs V, Carder PJ, Lansdown MR: Oestrogen receptor beta: how should we measure this? Br J Cancer 2002; 87: 687; author reply 688-689.
15. Hall JM, McDonnell DP: The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999; 140: 5566-5578.
16. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA: Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 2004; 10: 7490-7499.
17. Nemere I, Pietras RJ, Blackmore PF: Membrane receptors for steroid hormones: signal transduction and physiological significance. J Cell Biochem 2003; 88: 438-445.
18. Klinge CM: Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001; 29: 2905-2919.
19. Sanchez R, Nguyen D, Rocha W, White JH, Mader S: Diversity in the mechanisms of gene regulation by estrogen receptors. Bioessays 2002; 24: 244-254.
20. Klinge CM, Jernigan SC, Smith SL, Tyulmenkov VV, Kulakosky PC: Estrogen response element sequence impacts the conformation and transcriptional activity of estrogen receptor alpha(1). Mol Cell Endocrinol 2001; 174: 151-166.
21. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS: Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003; 144: 4562-4574.
22. McKenna NJ, Lanz RB, O'Malley BW: Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999; 20: 321-344.
23. Leo C, Chen JD: The SRC family of nuclear receptor coactivators. Gene 2000; 245: 1-211.
24. Chen JD, Evans RM: A transcriptional corepressor that interacts with nuclear hormone receptors. Nature 1995; 377: 371-374.
25. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK, et al: Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor corepressor. Nature 1995; 377: 397-404.
26. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P: Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000; 74: 311-317.
27. Ray P, Ghosh SK, Zhang DH, Ray A: Repression of interleukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription factors NFIL6 and NF-kappa B by the estrogen receptor. FEBS Lett 1997; 409: 79-85.
28. Safe S: Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor- Sp1 interactions. Vitam Horm 2001; 62: 231-252.
29. Figtree GA, McDonald D, Watkins H, Channon KM: Truncated estrogen receptor alpha 46-kDa isoform in human endothelial cells: relationship to acute activation of nitric oxide synthase. Circulation 2003; 107: 120-126.
30. Li L, Haynes MP, Bender JR: Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 2003; 100: 4807-4812.
31. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF: A variant of estrogen receptor-α, hER-α 36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA 2006; 103: 9063-9068.
32. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R: Mechanisms of tamoxifen resistance: increased estrogen receptor- HER2/neu cross-talk in ER/HER2- positive breast cancer. J Natl Cancer Inst 2004; 96: 926-935.
33. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C: Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem 2000; 275: 18447-18553.
34. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr: Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000; 14: 1649-1660.
35. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D, Ando S: The G proteincoupled receptor GPR30 mediates c-fos upregulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 2004; 279: 27008-27016.
36. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Ando S, Maggiolini M: The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17betaestradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 2006; 20: 631-646.
37. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ: Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 2002; 16: 116-127.
38. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV, Cheng JQ: Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 2001; 61: 5985-5991.
39. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F: Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. Embo J 1996; 15: 1292-1300.
40. Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA 2002; 99: 14783-14788.
41. Bunone G, Briand PA, Miksicek RJ, Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO Journal 1996; 15: 2174-2183.
42. Font de Mora J, Brown M: AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000; 20: 5041-5047.
43. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001; 276: 9817-9824.
44. Schiff R, Massarweh S, Shou J, Osborne CK: Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003; 9: 447S-454S. (Pubitemid 36105786)
45. Johnston SR: Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res 2005; 11: 889s-899s.
46. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen- activated protein kinase. Science 1995; 270: 1491-1494.
47. Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2: 101-112.
48. Weigel NL, Zhang Y: Ligand-independent activation of steroid hormone receptors. J Mol Med 1998; 76: 469-479.
49. Wu RC, Qin J, Hashimoto Y, Wong J, Xu J, Tsai SY, Tsai MJ, O'Malley BW: Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/ TRAM-1) coactivator activity by I kappa B kinase. Mol Cell Biol 2002; 22: 3549-3561.
50. Lopez GN, Turck CW, Schaufele F, Stallcup MR, Kushner PJ: Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity. J Biol Chem 2001; 276: 22177-22182.
51. Hong SH, Privalsky ML: The SMRT corepressor is regulated by a MEK-1 kinase pathway: inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export. Mol Cell Biol 2000; 20: 6612-6625.
52. Wu RC, Qin J, Yi P, Wong J, Tsai SY, Tsai MJ, O'Malley BW: Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell 2004; 15: 937-949.
53. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95: 353-361. (Pubitemid 36395255)
54. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S: A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005; 11: 4741-4748.
55. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM: HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004; 10: 5670-5676.
56. Ellis M: Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 2004; 9(suppl 3):20-26.
57. Prat A, Baselga J: The role of hormonal therapy in the management of hormonal-receptor- positive breast cancer with co-expression of Her2. Nat Clin Pract Oncol 2008; 5: 531-542.
58. Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO, Blamey RW: Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993; 7: 1018-1023.
59. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JF: Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 1995; 72: 1259-1266.
60. Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, Wyld P, Carney W: Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003; 21: 1967-1972.
61. Colomer R, Llombart-Cussac A, Lloveras B, et al: High Circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor- positive metastatic breast cancer: a confirmatory prospective study. Cancer 2007; 110: 2178-2185.
62. Dowsett M, Johnston S, Martin LA, Salter J, Hills M, Detre S, Gutierrez MC, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Smith I: Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. Endocr Relat Cancer 2005; 12(suppl 1):S113-S117.
63. Hu JC, Mokbel K: Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer? Eur J Surg Oncol 2001; 27: 335-337.
64. Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL, Allred DC: Her- 2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premeno - pausal women with operable breast cancer. J Clin Oncol 2003; 21: 453-457.
65. Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D, Norton L: HER- 2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000; 18: 3471-3479.
66. Dowsett M, Houghton J, Baum M, Salter J, A'Hern R, Iden C, Farndon J: ER, PgR, c- ERB2 and EGFR in patients randomized to adjuvant tamoxifen: combinations of biomarkers as discriminants of treatment benefit. Breast Cancer Res Treat 1999; 57: 61.
67. Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM: Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 2005; 11: 4835-4842.
68. Viale G, Regan M, Dell'Orto P, Del Curto B, Braye S, Orosz Z, Brown R, Olszewski WP, Knox F, Oehlschlegel C, Thürlimann B: Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant therapy for postmenopausal women with receptor positive breast cancer. 28th San Antonio Breast Cancer Symposium, San Antonio, 2005.
69. Rasmussen B: Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008; 9: 23-28.
70. Dowsett M: Biomarker investigations from the ATAC trial: the role of TA01. Breast Cancer Res Treat 2004; 87(suppl 1):S11-S18.
71. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 2008; 26: 1059-1065.
72. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-3816.
73. Zhu L, Chow LW, Loo WT, Guan XY, Toi M: Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. Clin Cancer Res 2004; 10: 4639-4644.
74. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter doubleblind randomized trial. J Clin Oncol 2005; 23: 5108-5116.
75. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE: Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer. A study from the IMPACT trialists. J Clin Oncol 2005; 23: 2477-2492.
76. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R: Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptorpositive, HER-2/neu-positive breast cancer. Cancer Res 2006; 66: 8266-8273.
77. Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM: Estrogen-independent proliferation is present in estrogen-receptor HER2- positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006;24: 3019-3025.
78. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M: Molecular changes in tamoxifen- resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen- activated protein kinase. J Clin Oncol 2005; 23: 2469-2476.